The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Healthy Subjects Clinical Trial

Official title:

An Open-label Phase 1 Study to Investigate the Effect of Moderate Hepatic Impairment Due to Liver Cirrhosis on the Pharmacokinetics of a Single Dose of 25 mg Aprocitentan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04252495
• Other study ID #: ID-080-109
• Secondary ID: 2019-003580-21
• Status: Completed
• Phase: Phase 1
• Start date: June 26, 2020
• Est. completion date: May 6, 2021

Study information

• Verified date: November 2022
• Source: Idorsia Pharmaceuticals Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: May 6, 2021
• Est. primary completion date: April 5, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 79 Years

Eligibility

Inclusion Criteria:

• Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.

• Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 and must agree to use highly effective methods of contraception from screening up to 30 days after study treatment.

• A Women of non-childbearing potential (WoNCBP) must meet one of the following criteria:

• Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy.

• Premature ovarian failure confirmed by a specialist gynecologist.

• Post-menopausal, defined as 12 consecutive months with amenorrhea prior to screening without alternative medical cause and confirmed with a follicle stimulating hormone test.

• Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening.

• Normal renal function confirmed by a creatinine clearance at screening according to Cockcroft and Gault adjusted to age.

• Additional principal inclusion criteria for subjects with moderate hepatic impairment (Group 1)

• Moderate hepatic function impairment due to liver cirrhosis defined as a score of 7-9 (inclusive) according to the Child-Pugh classification.

• Systolic blood pressure 95 to 160 mmHg, diastolic blood pressure 60 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose.

• International normalized ratio equal or less than 2.5 at screening.

• Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study.

• Additional principal inclusion criteria for healthy subjects (Group 2)

• Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.

Exclusion Criteria:

• Pregnant or lactating women.

• Previous exposure to aprocitentan and/or macitentan.

• Known hypersensitivity to any excipients of the drug formulation.

• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

• Any signs or symptoms of active, ongoing infection judged to be clinically relevant by the investigator (special attention should be given to COVID-19, e.g., fever, dry cough, dyspnea, sore throat, or fatigue).

• Subjects must adhere to the clinical site's house rules, which include, amongst others, polymerase chain reaction testing for SARS-CoV-2 at screening and admission.

• Legal incapacity or limited legal capacity at screening.

• Additional exclusion criteria for subjects with moderate hepatic impairment (Group 1)

• History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment except for those related to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not allowed).

• Hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.

• Clinical evidence or suspected acute liver failure as judged by the investigator.

• Encephalopathy grade greater than 2.

• Severe ascites and/or pleural effusion.

• Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening & on Day -1, except for those related to liver cirrhosis.

• Additional exclusion criteria for healthy subjects (Group 2)

• Clinically relevant findings on the physical examination at screening.

• History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).

• Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening & on Day -1.

• Clinically relevant abnormalities on a 12-lead ECG, recorded after 5 min in the supine position at screening & on Day 1 pre-dose.

Related Conditions & MeSH terms

• Healthy Subjects
• Hepatic Impairment
• Liver Diseases

Intervention

Drug:
• Aprocitentan
A single oral dose of 25 mg.

Locations

Country	Name	City	State
Germany	CRS Clinical Research Services Kiel GmbH	Kiel
Poland	Biokinetica S.A.	Jozefow

Sponsors (1)

Lead Sponsor	Collaborator
Idorsia Pharmaceuticals Ltd.

Countries where clinical trial is conducted

Germany,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum plasma concentration (Cmax) of aprocitentan		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.
Primary	Area under the plasma concentration-time curves (AUC0-t) of aprocitentan		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.
Primary	Area under the plasma concentration-time curve to infinity (AUC0 to inf) of aprocitentan		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.
Secondary	Treatment-emergent Adverse Events		From study treatment administration on Day 1 up to last assessment on End of Study (Day 15)